List of Figures List of Tables List of Abbreviations [Any acronyms or abbreviations used should also be defined the time they appear in the text.] 1. Summary [It is strongly recommended to address all elements outlined trial (whenever applicable) for any advice request, regardless of the scope of the questions. This summary will inform the background information section of the final advice letter. An upper limit of 3 pages for the summary is recommended] 1.1. Background information on the disease to be treated 1.1.1. Overview of the disease {} [Relevant epidemiological data, information on natural history of the disease and evolution on treatment should be discussed.] 1.1.2. Treatment options {} [The company should list all technologies (drugs, devices, procedures) that present relevant alternatives for the treatment of the pathology (stage, line of treatment) and discuss the current standard therapy with regard to the respective labelling status in Europe and North America. In the case of the existence of new treatments that are in advanced phases of development, this information should be included.]
List of Figures List of Tables List of Abbreviations [Any acronyms or abbreviations used should also be defined the time they appear in the text.] 1. Summary [It is strongly recommended to address all elements outlined (whenever applicable) for any advice request, regardless of the scope of the questions. This summary will inform the background information section of the final advice letter. An upper limit of 3 pages for the summary is recommended] 1.1. Background information on the disease to be treated 1.1.1. Overview of the disease {} [Relevant epidemiological data, information on natural history of the disease and evolution on treatment should be discussed.] 1.1.2. Treatment options {} [The company should list all technologies (drugs, devices, procedures) that present relevant alternatives for the treatment of the pathology (stage, line of treatment) and discuss the current standard therapy with regard to the respective labelling status in Europe and North America. In the case of the existence of new treatments that are in advanced phases of development, this information should be included.] trial
Multi-HTA-Pharma-Briefing-Book-Template_180227.docx